Search Results

There are 3277 results for: content related to: Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase

  1. You have free access to this content
    Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

    International Journal of Cancer

    Volume 130, Issue 8, 15 April 2012, Pages: 1948–1959, Benedetto Farsaci, Jack P. Higgins and James W. Hodge

    Version of Record online : 8 AUG 2011, DOI: 10.1002/ijc.26219

  2. You have full text access to this OnlineOpen article
    Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib

    Journal of Cellular and Molecular Medicine

    Volume 19, Issue 2, February 2015, Pages: 430–441, Eva Juengel, Dana Kim, Jasmina Makarević, Michael Reiter, Igor Tsaur, Georg Bartsch, Axel Haferkamp and Roman A. Blaheta

    Version of Record online : 2 DEC 2014, DOI: 10.1111/jcmm.12471

  3. You have full text access to this OnlineOpen article
    Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment

    Cancer Science

    Volume 106, Issue 2, February 2015, Pages: 160–170, Gökçe Hatipoglu, Stefan W. Hock, Ruth Weiss, Zheng Fan, Tina Sehm, Ali Ghoochani, Michael Buchfelder, Nicolai E. Savaskan and Ilker Y. Eyüpoglu

    Version of Record online : 15 FEB 2015, DOI: 10.1111/cas.12580

  4. You have free access to this content
    PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma- and melanoma-cell lines

    International Journal of Cancer

    Volume 131, Issue 2, 15 July 2012, Pages: E45–E55, Claus Bender and Axel Ullrich

    Version of Record online : 28 FEB 2012, DOI: 10.1002/ijc.26486

  5. You have free access to this content
    Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy

    International Journal of Cancer

    Volume 134, Issue 7, 01 April 2014, Pages: 1695–1705, Ritika Jaini, Patricia Rayman, Peter A. Cohen, James H. Finke and Vincent K. Tuohy

    Version of Record online : 8 OCT 2013, DOI: 10.1002/ijc.28488

  6. You have full text access to this OnlineOpen article
    Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction

    Cancer Medicine

    Volume 4, Issue 7, July 2015, Pages: 1003–1015, Esther A. Kleibeuker, Matthijs A. ten Hooven, Kitty C. Castricum, Richard Honeywell, Arjan W. Griffioen, Henk M. Verheul, Ben J. Slotman and Victor L. Thijssen

    Version of Record online : 31 MAR 2015, DOI: 10.1002/cam4.441

  7. You have full text access to this Open Access content
    Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene

    Cancer Science

    Volume 101, Issue 6, June 2010, Pages: 1493–1500, Haruka Kawahara, Kohji Noguchi, Kazuhiro Katayama, Junko Mitsuhashi and Yoshikazu Sugimoto

    Version of Record online : 22 FEB 2010, DOI: 10.1111/j.1349-7006.2010.01539.x

  8. You have free access to this content
    Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

    International Journal of Cancer

    Volume 130, Issue 1, 1 January 2012, Pages: 223–233, Seng Chuan Tang, Jurjen S. Lagas, Nienke A.G. Lankheet, Birk Poller, Michel J. Hillebrand, Hilde Rosing, Jos H. Beijnen and Alfred H. Schinkel

    Version of Record online : 7 APR 2011, DOI: 10.1002/ijc.26000

  9. You have free access to this content
    Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation

    BJU International

    Volume 112, Issue 2, July 2013, Pages: E211–E220, Iori Sakai, Hideaki Miyake and Masato Fujisawa

    Version of Record online : 10 JAN 2013, DOI: 10.1111/j.1464-410X.2012.11655.x

  10. You have free access to this content
    Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 2, June 2012, Pages: 132–144, Aiping ZHOU

    Version of Record online : 24 APR 2012, DOI: 10.1111/j.1743-7563.2012.01525.x

  11. Quantitation of sunitinib, an oral multitarget tyrosine kinase inhibitor, and its metabolite in urine samples by nonaqueous capillary electrophoresis time of flight mass spectrometry

    ELECTROPHORESIS

    Volume 36, Issue 14, July 2015, Pages: 1580–1587, Juana Rodríguez, Gregorio Castañeda, Lorena Muñoz and Jose C. Villa

    Version of Record online : 20 MAY 2015, DOI: 10.1002/elps.201400588

  12. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography–tandem mass spectrometry: application to a pharmacokinetic study

    Biomedical Chromatography

    Volume 26, Issue 11, November 2012, Pages: 1315–1324, Rana Rais, Ming Zhao, Ping He, Linping Xu, John F. Deeken and Michelle A. Rudek

    Version of Record online : 18 JAN 2012, DOI: 10.1002/bmc.2697

  13. You have free access to this content
    Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders

    British Journal of Pharmacology

    Volume 171, Issue 24, December 2014, Pages: 5757–5773, Wolf Wrasidlo, Leslie A Crews, Igor F Tsigelny, Emily Stocking, Valentina L Kouznetsova, Diana Price, Amy Paulino, Tania Gonzales, Cassia R Overk, Christina Patrick, Edward Rockenstein and Eliezer Masliah

    Version of Record online : 1 DEC 2014, DOI: 10.1111/bph.12875

  14. You have free access to this content
    In Vitro and In Vivo Evaluation of Targeted Sunitinib-Loaded Polymer Microbubbles Against Proliferation of Renal Cell Carcinoma

    Journal of Ultrasound in Medicine

    Volume 35, Issue 3, March 2016, Pages: 589–597, Jie Hu, Yujin Zong, Jun Li, Xiaodong Zhou, Jun Zhang, Ting Zhu, Mingke Jiao, Haili Su and Bin Bo

    Version of Record online : 1 MAR 2016, DOI: 10.7863/ultra.14.10038

  15. You have full text access to this Open Access content
    Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells

    Molecular Oncology

    Volume 6, Issue 5, October 2012, Pages: 530–541, Anabel Sorolla, Andrée Yeramian, Joan Valls, Xavier Dolcet, Laura Bergadà, Antoni Llombart-Cussac, Rosa Maria Martí, Xavier Matias-Guiu

    Version of Record online : 7 JUL 2012, DOI: 10.1016/j.molonc.2012.06.006

  16. You have free access to this content
    Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management

    Asia-Pacific Journal of Clinical Oncology

    Volume 3, Issue 4, December 2007, Pages: 167–176, Jayesh DESAI, Howard GURNEY, Nick PAVLAKIS, Grant A McARTHUR and Ian D DAVIS

    Version of Record online : 3 DEC 2007, DOI: 10.1111/j.1743-7563.2007.00136.x

  17. You have free access to this content
    Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662

    British Journal of Clinical Pharmacology

    Volume 79, Issue 5, May 2015, Pages: 809–819, Huixin Yu, Neeltje Steeghs, Jacqueline S. L. Kloth, Djoeke de Wit, J. G. Coen van Hasselt, Nielka P. van Erp, Jos H. Beijnen, Jan H. M. Schellens, Ron H. J. Mathijssen and Alwin D. R. Huitema

    Version of Record online : 22 APR 2015, DOI: 10.1111/bcp.12550

  18. Sunitinib Produces Neuroprotective Effect Via Inhibiting Nitric Oxide Overproduction

    CNS Neuroscience & Therapeutics

    Volume 20, Issue 3, March 2014, Pages: 244–252, Wei Cui, Zai-Jun Zhang, Sheng-Quan Hu, Shing-Hung Mak, Da-Ping Xu, Chung-Lit Choi, Yu-Qiang Wang, Wah-Keung Tsim, Ming-Yuen Lee, Jian-Hui Rong and Yi-Fan Han

    Version of Record online : 7 JAN 2014, DOI: 10.1111/cns.12203

  19. Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells

    The Prostate

    Volume 75, Issue 11, August 1, 2015, Pages: 1137–1149, Roque Diaz, Paul A. Nguewa, Miriam Redrado, Irene Manrique and Alfonso Calvo

    Version of Record online : 20 APR 2015, DOI: 10.1002/pros.22980

  20. Tyrosine kinase inhibitor sunitinib relieves systemic and oral antigen-induced anaphylaxes in mice

    Allergy

    Volume 67, Issue 1, January 2012, Pages: 114–122, K. Yamaki and S. Yoshino

    Version of Record online : 21 SEP 2011, DOI: 10.1111/j.1398-9995.2011.02717.x